Research programme: antibacterials - Rocket/XTL Biopharmaceuticals

Drug Profile

Research programme: antibacterials - Rocket/XTL Biopharmaceuticals

Alternative Names: Antibacterials research programme - Rocket/XTL Biopharmaceuticals; Human monoclonal immunotherapies research programme - Rocket/XTL Biopharmaceuticals

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inotek Pharmaceuticals; XTL Biopharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gram-negative infections

Most Recent Events

  • 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
  • 08 Oct 2007 Discontinued - Preclinical for Gram-negative infections in Israel (unspecified route)
  • 08 Oct 2007 Discontinued - Preclinical for Gram-negative infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top